MEI Pharma Inc logo

MEI Pharma Inc

$ 0.42 +0.0186 (+4.63%) 04:00 PM EST
P/E:
At Loss
P/B:
1.07
Market Cap:
$ 56.00M
Enterprise V:
$ -90.09M
Volume:
550.22K
Avg Vol (2M):
810.72K
Also Trade In:
Volume:
550.22K
Market Cap $:
56.00M
PE Ratio:
At Loss
Avg Vol (2-Month):
810.72K
Enterprise Value $:
-90.09M
PB Ratio:
1.07
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Financials (Next Earnings Date:2022-11-10 Est.)

MEIP's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MEIP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 40.697
EPS (TTM) ($) -0.51
Beta 0.93
Volatility % 92.1
14-Day RSI 37.26
14-Day ATR ($) 0.03584
20-Day SMA ($) 0.456895
12-1 Month Momentum % -81.14
52-Week Range ($) 0.3825 - 3.55
Shares Outstanding (Mil) 133.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

MEI Pharma Inc Filings

Document Form Filing Date
No Filing Data

MEI Pharma Inc Analysis

Share your research

Headlines

See More
No news.